

Candidate: Regional Treasurer, Asia (2023-2026)



Clare Tan, BSc

Director, Global Clinical Operations
Tessa Therapeutics Ltd
Singapore

Summary of academic and professional background:

I graduated from National University of Singapore in 2004 with a Bachelor of Science in Life Sciences, with specialization in Biomedical Science (BMS); Molecular and Cell Biology (MCB).

I have been running clinical trials in clinical operations and project management for more than 19 years. Most recently, as the Director of Global Clinical Operations at Tessa Therapeutics, I have been managing global cell therapy studies, focusing on EBVSTs and CAR-T treatments in oncology disease. I oversee global CROs and servicing vendors, and work closely with KOLs and sites across US, Asia and EU.

Prior to joining Tessa, I headed the Asia Pacific (APAC) Early Clinical Development team in LabCorp to run global Immuno-Oncology, Rare Diseases and Epidemiology studies within APAC. I was also leading the clinical operations team in Southeast Asia region during the earlier part of my career at PPD.

Affiliated professional and commercial associations and any perceived or potential conflict of interests:

N/A

List of top notable contributions to the field (e.g. publications, patents, reports, products advanced to clinical trial or regulatory approval, asset development, mergers, acquisitions, etc.) from the last 10 years:

Clinical Trial Approvals

- I have driven many successful global clinical trial approvals at both local and central IRBs at the respective countries in APAC and US, most of which are oncology trials.
- The most recent trials are:
 - A Multicenter, Randomized, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Autologous Epstein-Barr Virus-specific Cytotoxic T Cells versus Gemcitabine and Carboplatin as First Line Treatment for Advanced Nasopharyngeal Carcinoma Patients: Singapore, Malaysia, Thailand, Taiwan and US
 - A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically-Modified Autologous T Cells (CD30.CAR-T) in Adult and

Pediatric Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
(CHARIOT – TESSCAR001): US.

Conference Presentations:

I do present at global and regional conferences, sharing my area of expertise with global participants within the industry:

- Clinical Operations in Oncology Trials Virtual Conference - US and EU - 01 Dec 2021 : Topic- CRO Oversight in CAR-T studies
- Outsourcing in clinical trials and clinical supply in East Asia - Seoul - 29-30 Nov 2022: Topic - Working with CRO and third-party vendors in executing autologous CAR-T Therapy Trials.
- Clinical Trials Festival Asia 2023 - Singapore -14 to 16 Mar 2023: Enhancing Operation Efficiency in Cell and Gene Therapy Trial through continuous improvement (Upcoming presentation)

Panel Discussions:

I have also hosted a panel discussion at the 19th CRCS Forum @APREC - Singapore - 09 Mar 2012: Topic - Investigator's Delegated Responsibilities at the site.

Summary of involvement with ISCT in the past five years:

- 1) I was an ISCT mentor for two ISCT members in APAC in 2022 - 1) JingJing Li, a post-doc from University of New South Wales. 2) Dr. Ram Mohan Jaiswal, an MD and trained pathologist at Mahatma Gandhi Medical College. Although I am in a complete different field with my mentees, I took time to understand their needs and helped them in ways I could support. JingJing was exploring how industry could help her grow in her area of expertise, while Dr. Ram wanted to improvise his hospital facilities in preparation for gene and cell therapy trials or treatment in future. I shared with them my perspective of industry development, and I arranged sessions for them to chat with people I knew who were once in their position and had moved on into the industry. Through ISCT, I introduced to Dr. Ram the program ACTRIS Singapore offers to train up experts in hospitals and healthcare industry for gene and cell therapy facilities set-up. I shared with them good webinars that suited them and they did likewise. Those activities widened their views of what else they could do.
- 2) I attended ISCT virtual conference in 2020.
- 3) I attended a number of ISCT webinars such as "Extending CAR-T Therapies to Hodgkin & T Cell Lymphoma", and "Requirements, Regulatory Strategies and Best Practices for Cell Therapy Clinical Trials in the APAC Region".

Summary of strategic vision for the Global Society:

- To connect Pharma and Biotechs which are developing cell and gene therapy product together as a community within ISCT Asia - a platform for networking, potential collaboration and mutual learning.
- To identify the key challenges/needs of the clinicians, researchers, regulators, technologists, and industry partners within the region, and review as a committee in Asia region how we can support their needs.
- To promote ISCT membership to the relevant parties within the region through seminars, webinars and social media.